We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Regeneron Halts Enrollment of Severe Patients in COVID-19 Antibody Trial Following Possible Safety Signal
Regeneron Halts Enrollment of Severe Patients in COVID-19 Antibody Trial Following Possible Safety Signal
Despite announcing positive results for its phase 2/3 COVID-19 antibody cocktail trial Thursday, a potential safety signal has led Regeneron to temporarily stop enrolling patients who require high-flow oxygen or mechanical ventilation.